Dapagliflozin (Farxiga) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor commonly used in the treatment of type 2 diabetes mellitus (T2DM). The gene discussed is SLC5A2; the disease is diabetes mellitus.